<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>OFEV- nintedanib capsule </strong><br>Boehringer Ingelheim Pharmaceuticals, Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information
needed to use OFEV safely and effectively.  See full prescribing information
for OFEV.<br><br>OFEV<span class="Sup">®</span> (nintedanib)
capsules, for oral use<br>Initial U.S. Approval: 2014<br><br>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">OFEV is a kinase inhibitor indicated
for the treatment of <span class="product-label-link" type="condition" conceptid="45763750" conceptname="Idiopathic pulmonary fibrosis">idiopathic pulmonary fibrosis</span> (IPF). (<a href="#Section_1">1</a>) </p>
<br>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul class="Disc">
<li>Recommended dosage: 150 mg twice daily approximately 12
hours apart taken with food. (<a href="#Section_2.2">2.2</a>)</li>
<li>Consider temporary dose reduction to 100 mg, treatment interruption,
or discontinuation for management of adverse reactions. (<a href="#Section_2.3">2.3</a>, <a href="#Section_5.1">5.1</a>, <a href="#Section_5.2">5.2</a>, <a href="#Section_6">6</a>)</li>
<li>Prior to treatment, conduct liver function tests. (<a href="#Section_2.1">2.1</a>, <a href="#Section_5.1">5.1</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div>
<p class="Highlighta">Capsules: 150 mg and 100 mg (<a href="#Section_3">3</a>) </p>
<br>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><p class="Highlighta">None<a href="#Section_4"></a> </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div>
<ul class="Disc">
<li>Elevated liver enzymes: ALT, AST, and bilirubin elevations
have occurred with OFEV. Monitor ALT, AST, and bilirubin before and
during treatment. Temporary dosage reductions or discontinuations
may be required. (<a href="#Section_2.1">2.1</a>, <a href="#Section_5.1">5.1</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal disorders</span>: <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>
have occurred with OFEV. Treat patients at first signs with adequate
hydration and antidiarrheal medicine (e.g., loperamide) or anti-emetics.
Discontinue OFEV if severe <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> persists
despite symptomatic treatment. (<a href="#Section_5.2">5.2</a>)</li>
<li>Embryofetal toxicity: Women of childbearing potential should
be advised of the potential hazard to the fetus and to avoid becoming
pregnant. (<a href="#Section_5.3">5.3</a>)</li>
<li>Arterial <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">thromboembolic events</span> have been reported. Use caution
when treating patients at higher cardiovascular risk including known
<span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span>. (<a href="#Section_5.4">5.4</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> events have been reported. Use OFEV in patients
with known <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> risk only if anticipated benefit outweighs the
potential risk. (<a href="#Section_5.5">5.5</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="4202064" conceptname="Gastrointestinal perforation">Gastrointestinal perforation</span> has been reported. Use OFEV
with caution when treating patients with recent abdominal surgery.
Discontinue OFEV in patients who develop <span class="product-label-link" type="condition" conceptid="4202064" conceptname="Gastrointestinal perforation">gastrointestinal perforation</span>.
Only use OFEV in patients with known risk of <span class="product-label-link" type="condition" conceptid="4202064" conceptname="Gastrointestinal perforation">gastrointestinal perforation</span>
if the anticipated benefit outweighs the potential risk. (<a href="#Section_5.6">5.6</a>)</li>
</ul>
<br>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">Most common adverse reactions (≥5%) are: <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>,
<span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, liver enzyme elevation, decreased
appetite, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight decreased</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>. (<a href="#Section_6.1">6.1</a>) </p>
<br><p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS,
contact Boehringer Ingelheim Pharmaceuticals, Inc. at (800) 542-6257
or (800) 459-9906 TTY or FDA at 1-800-FDA-1088 or <span class="Italics"><a href="#www.fda.gov/medwatch">www.fda.gov/medwatch</a></span>.</span> </p>
<br>
</div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul class="Disc"><li>Coadministration of P-gp and CYP3A4 inhibitors may increase
nintedanib exposure. Monitor patients closely for tolerability of
OFEV. (<a href="#Section_7.1">7.1</a>)</li></ul></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div>
<ul class="Disc">
<li>Nursing mothers: Discontinue nursing or discontinue the
drug, taking into account the importance of the drug to the mother.
(<a href="#Section_8.3">8.3</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic impairment</span>: Monitor for adverse reactions and consider
dose modification or discontinuation of OFEV as needed for patients
with mild <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. OFEV is not recommended for use in patients
with moderate or severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. (<a href="#Section_8.6">8.6</a>, <a href="#Section_12.3">12.3</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal impairment</span>: The safety and efficacy of OFEV have not
been studied in patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> and end-stage
<span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>. (<a href="#Section_8.7">8.7</a>, <a href="#Section_12.3">12.3</a>)</li>
<li>Smokers: Decreased exposure has been noted in smokers which
may alter the efficacy profile of OFEV. (<a href="#Section_8.8">8.8</a>)</li>
</ul>
<br><br>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.</p>
<p class="HighlightsRevision">Revised: 10/2014</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1  INDICATIONS
AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2  DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1  Testing Prior to
OFEV Administration</a></h2>
<h2><a href="#section-2.2" class="toc">2.2  Recommended Dosage</a></h2>
<h2><a href="#section-2.3" class="toc">2.3  Dosage Modification due to Adverse Reactions</a></h2>
<h1><a href="#section-3" class="toc">3  DOSAGE
FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4  CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5  WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1  Elevated Liver Enzymes</a></h2>
<h2><a href="#section-5.2" class="toc">5.2  Gastrointestinal
Disorders</a></h2>
<h2><a href="#section-5.3" class="toc">5.3  Embryofetal Toxicity</a></h2>
<h2><a href="#section-5.4" class="toc">5.4  Arterial Thromboembolic
Events</a></h2>
<h2><a href="#section-5.5" class="toc">5.5  Risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span></a></h2>
<h2><a href="#section-5.6" class="toc">5.6  Gastrointestinal
Perforation</a></h2>
<h1><a href="#section-6" class="toc">6  ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1  Clinical Trials Experience</a></h2>
<h1><a href="#section-7" class="toc">7  DRUG
INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1  P-glycoprotein (P-gp)
and CYP3A4 Inhibitors and Inducers</a></h2>
<h2><a href="#section-7.2" class="toc">7.2  Anticoagulants</a></h2>
<h1><a href="#section-8" class="toc">8  USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1  Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3  Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4  Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5  Geriatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.6  <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h2><a href="#section-8.6" class="toc">8.7  <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h2><a href="#section-8.7" class="toc">8.8  Smokers</a></h2>
<h1><a href="#section-9" class="toc">10  OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11  DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12  CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1  Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.2  Pharmacodynamics</a></h2>
<h2><a href="#section-11.3" class="toc">12.3  Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13  NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1  Carcinogenesis, Mutagenesis, Impairment of
Fertility</a></h2>
<h1><a href="#section-13" class="toc">14  CLINICAL STUDIES</a></h1>
<h1><a href="#section-14" class="toc">16  HOW
SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-15" class="toc">17  PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="Section_1"></a><a name="section-1"></a><p></p>
<h1>1  INDICATIONS
AND USAGE</h1>
<p class="First"><a name="P5"></a>OFEV is indicated
for the treatment of <span class="product-label-link" type="condition" conceptid="45763750" conceptname="Idiopathic pulmonary fibrosis">idiopathic pulmonary fibrosis</span> (IPF).</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="Section_2"></a><a name="section-2"></a><p></p>
<h1>2  DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_2.1"></a><a name="section-2.1"></a><p></p>
<h2>2.1  Testing Prior to
OFEV Administration</h2>
<p class="First"><a name="p217281397663030"></a>Conduct liver function tests prior to initiating treatment with OFEV <span class="Italics">[see Warnings and Precautions (<a href="#Section_5.1">5.1</a>)].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_2.2"></a><a name="section-2.2"></a><p></p>
<h2>2.2  Recommended Dosage</h2>
<p class="First"><a name="p48983281397663231"></a>The recommended dosage of OFEV
is 150 mg twice daily administered approximately 12 hours apart.</p>
<p><a name="p49074281397663273"></a>OFEV capsules should be taken
with food <span class="Italics">[see Clinical Pharmacology (<a href="#Section_12.3">12.3</a>)]</span> and swallowed whole with liquid. OFEV capsules
should not be chewed or crushed because of a bitter taste. The effect
of chewing or crushing of the capsule on the pharmacokinetics of nintedanib
is not known.</p>
<p><a name="p5353281413555053"></a>If a dose
of OFEV is missed, the next dose should be taken at the next scheduled
time. Advise the patient to not make up for a missed dose. Do not
exceed the recommended maximum daily dosage of 300 mg.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_2.3"></a><a name="section-2.3"></a><p></p>
<h2>2.3  Dosage Modification due to Adverse Reactions</h2>
<p class="First"><a name="p5344281413555966"></a>In addition to symptomatic treatment,
if applicable, the management of adverse reactions of OFEV may require
dose reduction or temporary interruption until the specific adverse
reaction resolves to levels that allow continuation of therapy. OFEV
treatment may be resumed at the full dosage (150 mg twice daily),
or at the reduced dosage (100 mg twice daily), which subsequently
may be increased to the full dosage. If a patient does not tolerate
100 mg twice daily, discontinue treatment with OFEV <span class="Italics">[see Warnings
and Precautions (<a href="#Section_5.1">5.1</a>, <a href="#Section_5.2">5.2</a>, <a href="#Section_5.4">5.4</a>, <a href="#Section_5.6">5.6</a>) and Adverse Reactions (<a href="#Section_6.1">6.1</a>)]</span>.</p>
<p><a name="p5167281413555963"></a>Dose modifications or interruptions may be
necessary for liver enzyme elevations. For <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">aspartate aminotransferase</span>
(AST) or <span class="product-label-link" type="condition" conceptid="4211515" conceptname="Alanine aminotransferase">alanine aminotransferase</span> (ALT) &gt;3 times to &lt;5 times the
upper limit of normal (ULN) without signs of severe <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver damage</span>,
interrupt treatment or reduce OFEV to 100 mg twice daily. Once liver
enzymes have returned to baseline values, treatment with OFEV may
be reintroduced at a reduced dosage (100 mg twice daily), which subsequently
may be increased to the full dosage (150 mg twice daily) <span class="Italics">[see
Warnings and Precautions (<a href="#Section_5.1">5.1</a>) and
Adverse Reactions (<a href="#Section_6.1">6.1</a>)].</span> Discontinue OFEV for AST or ALT elevations &gt;5 times ULN or &gt;3 times
ULN with signs or symptoms of severe <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver damage</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="Section_3"></a><a name="section-3"></a><p></p>
<h1>3  DOSAGE
FORMS AND STRENGTHS</h1>
<p class="First"><a name="P7"></a>150 mg
capsules:  brown, opaque, oblong, soft capsules imprinted in black
with the Boehringer Ingelheim company symbol and "150".</p>
<p><a name="p51204281397663320"></a>100 mg capsules:  peach, opaque,
oblong, soft capsules imprinted in black with the Boehringer Ingelheim
company symbol and "100".</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="Section_4"></a><a name="section-4"></a><p></p>
<h1>4  CONTRAINDICATIONS</h1>
<p class="First"><a name="P8"></a>None</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="Section_5"></a><a name="section-5"></a><p></p>
<h1>5  WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.1"></a><a name="section-5.1"></a><p></p>
<h2>5.1  Elevated Liver Enzymes</h2>
<p class="First"><a name="p51392281397663763"></a>The safety and efficacy of OFEV
has not been studied in patients with moderate (Child Pugh B) or severe
(Child Pugh C) <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. Treatment with OFEV is not recommended
in patients with moderate or severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span><span class="Italics"> [see
Use in Specific Populations (<a href="#Section_8.6">8.6</a>)
and Clinical Pharmacology (<a href="#Section_12.3">12.3</a>)].</span></p>
<p><a name="p56731281397663765"></a>In clinical trials,
administration of OFEV was associated with elevations of liver enzymes
(ALT, AST, ALKP, GGT). Liver enzyme increases were reversible with
dose modification or interruption and not associated with clinical
signs or symptoms of <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver injury</span>. The majority (94%) of patients
with ALT and/or AST elevations had elevations &lt;5 times ULN. Administration
of OFEV was also associated with elevations of bilirubin. The majority
(95%) of patients with bilirubin elevations had elevations &lt;2 times
ULN <span class="Italics">[see Use in Specific Populations (<a href="#Section_8.6">8.6</a>) and Clinical Pharmacology (<a href="#Section_12.3">12.3</a>)].</span></p>
<p><a name="p13053281413557542"></a>Conduct liver function tests (ALT, AST, and bilirubin) prior to treatment
with OFEV, monthly for 3 months, and every 3 months thereafter, and
as clinically indicated. Dosage modifications or interruption may
be necessary for liver enzyme elevations <span class="Italics">[see Dosage and Administration
(<a href="#Section_2.1">2.1</a>, <a href="#Section_2.3">2.3</a>)].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.2"></a><a name="section-5.2"></a><p></p>
<h2>5.2  Gastrointestinal
Disorders</h2>
<p class="First"><a name="p56744281397663806"></a><span class="Underline"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></span><br><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> was the most frequent gastrointestinal
event reported in 62% versus 18% of patients treated with OFEV and
placebo, respectively <span class="Italics">[see Adverse Reactions (<a href="#Section_6.1">6.1</a>)].</span> In most patients, the event
was of mild to moderate intensity and occurred within the first 3
months of treatment. <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> led to permanent dose reduction in 11%
of patients treated with OFEV compared to 0 placebo-treated patients.
<span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> led to discontinuation of OFEV in 5% of the patients compared
to &lt;1% of placebo-treated patients.</p>
<p><a name="p58932281397663821"></a>Dosage modifications or treatment interruptions
may be necessary in patients with adverse reactions of <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>. Treat
<span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> at first signs with adequate hydration and antidiarrheal
medication (e.g., loperamide), and consider treatment interruption
if <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> continues <span class="Italics">[see Dosage and Administration (<a href="#Section_2.3">2.3</a>)].</span> OFEV treatment may be resumed
at the full dosage (150 mg twice daily), or at the reduced dosage
(100 mg twice daily), which subsequently may be increased to the full
dosage. If severe <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> persists despite symptomatic treatment,
discontinue treatment with OFEV.</p>
<p><a name="p58943281397663862"></a><span class="Underline"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></span><br><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> was reported in 24% versus 7% and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> was
reported in 12% versus 3% of patients treated with OFEV and placebo,
respectively <span class="Italics">[see Adverse Reactions (<a href="#Section_6.1">6.1</a>)]</span>. In most patients, these events were of mild
to moderate intensity. <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> led to discontinuation of OFEV in 2%
of patients. <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span> led to discontinuation of OFEV in 1% of the
patients.</p>
<p><a name="p58973281397663870"></a>For <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>
or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> that persists despite appropriate supportive care including
anti-emetic therapy, dose reduction or treatment interruption may
be required <span class="Italics">[see Dosage and Administration (<a href="#Section_2.3">2.3</a>)]</span>. OFEV treatment may be resumed
at the full dosage (150 mg twice daily), or at the reduced dosage
(100 mg twice daily), which subsequently may be increased to the full
dosage. If severe <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> does not resolve, discontinue
treatment with OFEV.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.3"></a><a name="section-5.3"></a><p></p>
<h2>5.3  Embryofetal Toxicity</h2>
<p class="First"><a name="p59014281397663946"></a>OFEV can cause fetal harm when
administered to a pregnant woman. Nintedanib was teratogenic and embryofetocidal
in rats and rabbits at less than and approximately 5 times the maximum
recommended human dose (MRHD) in adults (on an AUC basis at oral doses
of 2.5 and 15 mg/kg/day in rats and rabbits, respectively). If OFEV
is used during pregnancy, or if the patient becomes pregnant while
taking OFEV, the patient should be advised of the potential hazard
to a fetus. Women of childbearing potential should be advised to avoid
becoming pregnant while receiving treatment with OFEV and to use adequate
contraception during treatment and at least 3 months after the last
dose of OFEV <span class="Italics">[see Use in Specific Populations (<a href="#Section_8.1">8.1</a>)].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.4"></a><a name="section-5.4"></a><p></p>
<h2>5.4  Arterial Thromboembolic
Events</h2>
<p class="First"><a name="p59303281397664103"></a>Arterial
<span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">thromboembolic events</span> have been reported in patients taking OFEV.
In clinical trials, arterial <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">thromboembolic events</span> were reported in
2.5% of patients treated with OFEV and 0.8% of placebo-treated patients.
<span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial infarction</span> was the most common adverse reaction under arterial
<span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">thromboembolic events</span>, occurring in 1.5% of OFEV-treated patients
compared to 0.4% of placebo-treated patients.</p>
<p><a name="p53838281397664162"></a>Use caution when treating patients at higher
cardiovascular risk including known <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span>. Consider
treatment interruption in patients who develop signs or symptoms of
<span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">acute myocardial ischemia</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.5"></a><a name="section-5.5"></a><p></p>
<h2>5.5  Risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span></h2>
<p class="First"><a name="p61578281397664210"></a>Based on the mechanism of action (VEGFR inhibition),
OFEV may increase the risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. In clinical trials, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>
events were reported in 10% of patients treated with OFEV and in 7%
of patients treated with placebo.</p>
<p><a name="p61674281397664235"></a>Use OFEV in patients with known risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>
only if the anticipated benefit outweighs the potential risk.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.6"></a><a name="section-5.6"></a><p></p>
<h2>5.6  Gastrointestinal
Perforation</h2>
<p class="First"><a name="p20625281413558292"></a>Based on the mechanism of action, OFEV may increase the risk of gastrointestinal
perforation. In clinical trials, <span class="product-label-link" type="condition" conceptid="4202064" conceptname="Gastrointestinal perforation">gastrointestinal perforation</span> was
reported in 0.3% of patients treated with OFEV, compared to 0 cases
in the placebo-treated patients.</p>
<p><a name="p61633281397664218"></a>Use caution when treating patients who have
had recent abdominal surgery. Discontinue therapy with OFEV in patients
who develop <span class="product-label-link" type="condition" conceptid="4202064" conceptname="Gastrointestinal perforation">gastrointestinal perforation</span>. Only use OFEV in patients
with known risk of <span class="product-label-link" type="condition" conceptid="4202064" conceptname="Gastrointestinal perforation">gastrointestinal perforation</span> if the anticipated
benefit outweighs the potential risk.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="Section_6"></a><a name="section-6"></a><p></p>
<h1>6  ADVERSE REACTIONS</h1>
<p class="First"><a name="P10"></a>The following adverse reactions are discussed in greater
detail in other sections of the labeling:</p>
<ul class="Disc">
<li>Liver Enzyme and Bilirubin Elevations <span class="Italics">[see Warnings
and Precautions <a href="#Section_5.1">(5.1)</a>]</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span> <span class="Italics">[see Warnings and Precautions
(<a href="#Section_5.2">5.2</a>)]</span>
</li>
<li>Embryofetal Toxicity <span class="Italics">[see Warnings and Precautions
(<a href="#Section_5.3">5.3</a>)]</span>
</li>
<li>Arterial <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">Thromboembolic Events</span> <span class="Italics">[see Warnings and
Precautions (<a href="#Section_5.4">5.4</a>)]</span>
</li>
<li>Risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> <span class="Italics">[see Warnings and Precautions (<a href="#Section_5.5">5.5</a>)]</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="4202064" conceptname="Gastrointestinal perforation">Gastrointestinal Perforation</span> <span class="Italics">[see Warnings and Precautions
(<a href="#Section_5.6">5.6</a>)]</span>
</li>
</ul>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_6.1"></a><a name="section-6.1"></a><p></p>
<h2>6.1  Clinical Trials Experience</h2>
<p class="First"><a name="p56397281397664607"></a>Because clinical trials are conducted under
widely varying conditions, adverse reaction rates observed in the
clinical trials of a drug cannot be directly compared to rates in
the clinical trials of another drug and may not reflect the rates
observed in practice.</p>
<p><a name="p66783281397664629"></a>The safety of OFEV was evaluated in over 1000 IPF patients with over
200 patients exposed to OFEV for more than 2 years in clinical trials.</p>
<p><a name="p66814281397664673"></a>OFEV was studied in three randomized,
double-blind, placebo-controlled, 52-week trials. In the phase 2 (Study
1) and phase 3 (Studies 2 and 3) trials, 723 patients with IPF received
OFEV 150 mg twice daily and 508 patients received placebo. The median
duration of exposure was 10 months for patients treated with OFEV
and 11 months for patients treated with placebo. Subjects ranged in
age from 42 to 89 years (median age of 67 years). Most patients were
male (79%) and Caucasian (60%).</p>
<p><a name="p66844281397664712"></a>The most frequent serious adverse reactions
reported in patients treated with OFEV, more than placebo, were <span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">bronchitis</span>
(1.2% vs. 0.8%) and <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> (1.5% vs. 0.4%). The most
common adverse events leading to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> in patients treated with OFEV,
more than placebo, were <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> (0.7% vs. 0.6%), <span class="product-label-link" type="condition" conceptid="4128888" conceptname="Neoplasm of lung">lung neoplasm</span> malignant
(0.3% vs. 0%), and <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> (0.3% vs. 0.2%). In the predefined
category of major adverse cardiovascular events (MACE) including MI,
fatal events were reported in 0.6% of OFEV-treated patients and 1.8%
of placebo-treated patients.</p>
<p><a name="p66874281397664724"></a>Adverse reactions leading to permanent dose
reductions were reported in 16% of OFEV-treated patients and 1% of
placebo-treated patients. The most frequent adverse reaction that
led to permanent dose reduction in the patients treated with OFEV
was <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (11%).</p>
<p><a name="p66904281397664745"></a>Adverse reactions leading to discontinuation were reported in 21%
of OFEV-treated patients and 15% of placebo-treated patients. The
most frequent adverse reactions that led to discontinuation in OFEV-treated
patients were <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (5%), <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (2%), and <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">decreased appetite</span> (2%).</p>
<p><a name="p1588511281413558544"></a>The most common adverse reactions
with an incidence of ≥5% and more frequent in the OFEV than placebo
treatment group are listed in Table 1.</p>
<a name="t6694428"></a><table border="0" frame="void" rules="none" width="100%">
<caption><span>Table 1 Adverse Reactions Occurring in ≥5% of OFEV-treated
Patients and More Commonly Than Placebo in Studies 1, 2, and 3</span></caption>
<colgroup>
<col width="5%">
<col width="29*">
<col align="center" width="32%">
<col align="center" width="32%">
</colgroup>
<tfoot><tr class="First Last"><td colspan="4">
<span class="Sup">a</span> Includes <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>,
<span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">abdominal pain upper</span>, <span class="product-label-link" type="condition" conceptid="193322" conceptname="Right lower quadrant pain">abdominal pain lower</span>, <span class="product-label-link" type="condition" conceptid="4091963" conceptname="Bowel spasm">gastrointestinal pain</span>
and <span class="product-label-link" type="condition" conceptid="197981" conceptname="Abdominal tenderness">abdominal tenderness</span>.<br><span class="Sup">b</span> Includes
gamma-glutamyltransferase increased, hepatic enzyme increased, alanine
aminotransferase increased, <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">aspartate aminotransferase</span> increased,
<span class="product-label-link" type="condition" conceptid="4326594" conceptname="Abnormal liver function">hepatic function abnormal</span>, <span class="product-label-link" type="condition" conceptid="438878" conceptname="Liver function tests abnormal">liver function test abnormal</span>, transaminase
increased, blood alkaline phosphatase-increased, <span class="product-label-link" type="condition" conceptid="4211515" conceptname="Alanine aminotransferase">alanine aminotransferase</span>
abnormal, <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">aspartate aminotransferase</span> abnormal, and gamma-glutamyltransferase
abnormal.<br><span class="Sup">c</span> Includes <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>,
<span class="product-label-link" type="condition" conceptid="141693" conceptname="Elevated blood-pressure reading without diagnosis of hypertension">blood pressure increased</span>, <span class="product-label-link" type="condition" conceptid="312938" conceptname="Hypertensive encephalopathy">hypertensive crisis</span>, and hypertensive <span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">cardiomyopathy</span>.</td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" colspan="2" valign="top"><span class="Bold">Adverse Reaction</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><span class="Bold">OFEV, 150 mg<br>n=723</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><span class="Bold">Placebo<br>n=508</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" colspan="2"><span class="Bold">Gastrointestinal
disorders</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"> </td>
<td class="Botrule Lrule Rrule Toprule" align="center"> </td>
</tr>
<tr>
<td class="Botrule Lrule Toprule"> </td>
<td class="Botrule Rrule Toprule"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">62%</td>
<td class="Botrule Lrule Rrule Toprule" align="center">18%</td>
</tr>
<tr>
<td class="Botrule Lrule Toprule"> </td>
<td class="Botrule Rrule Toprule"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">24%</td>
<td class="Botrule Lrule Rrule Toprule" align="center">7%</td>
</tr>
<tr>
<td class="Botrule Lrule Toprule"> </td>
<td class="Botrule Rrule Toprule"><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span><span class="Sup">a</span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">15%</td>
<td class="Botrule Lrule Rrule Toprule" align="center">6%</td>
</tr>
<tr>
<td class="Botrule Lrule Toprule"> </td>
<td class="Botrule Rrule Toprule"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">12%</td>
<td class="Botrule Lrule Rrule Toprule" align="center">3%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" colspan="2"><span class="Bold">Hepatobiliary
disorders</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"> </td>
<td class="Botrule Lrule Rrule Toprule" align="center"> </td>
</tr>
<tr>
<td class="Botrule Lrule Toprule"> </td>
<td class="Botrule Rrule Toprule">Liver enzyme elevation<span class="Sup">b</span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">14%</td>
<td class="Botrule Lrule Rrule Toprule" align="center">3%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" colspan="2"><span class="Bold">Metabolism
and nutrition disorders</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"> </td>
<td class="Botrule Lrule Rrule Toprule" align="center"> </td>
</tr>
<tr>
<td class="Botrule Lrule Toprule"> </td>
<td class="Botrule Rrule Toprule"><span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Decreased appetite</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">11%</td>
<td class="Botrule Lrule Rrule Toprule" align="center">5%</td>
</tr>
<tr>
<td class="Botrule Lrule Toprule" colspan="2"><span class="Bold">Nervous systemic
disorders</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"> </td>
<td class="Botrule Lrule Rrule Toprule" align="center"> </td>
</tr>
<tr>
<td class="Botrule Lrule Toprule"> </td>
<td class="Botrule Rrule Toprule"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">8%</td>
<td class="Botrule Lrule Rrule Toprule" align="center">5%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" colspan="2"><span class="Bold">Investigations</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"> </td>
<td class="Botrule Lrule Rrule Toprule" align="center"> </td>
</tr>
<tr>
<td class="Botrule Lrule Toprule"> </td>
<td class="Botrule Rrule Toprule"><span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">Weight decreased</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">10%</td>
<td class="Botrule Lrule Rrule Toprule" align="center">3%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" colspan="2"><span class="Bold"><span class="product-label-link" type="condition" conceptid="443784" conceptname="Vascular disorder">Vascular disorders</span></span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"> </td>
<td class="Botrule Lrule Rrule Toprule" align="center"> </td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Toprule"> </td>
<td class="Botrule Rrule Toprule"><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span><span class="Sup">c</span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">5%</td>
<td class="Botrule Lrule Rrule Toprule" align="center">4%</td>
</tr>
</tbody>
</table>
<p><a name="p146077281413558806"></a>In addition, <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">hypothyroidism</span>
was reported in patients treated with OFEV, more than placebo (1.1%
vs. 0.6%).</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="Section_7"></a><a name="section-7"></a><p></p>
<h1>7  DRUG
INTERACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_7.1"></a><a name="section-7.1"></a><p></p>
<h2>7.1  P-glycoprotein (P-gp)
and CYP3A4 Inhibitors and Inducers</h2>
<p class="First"><a name="p30960281397666153"></a>Nintedanib is a substrate of P-gp and, to
a minor extent, CYP3A4 <span class="Italics">[see Clinical Pharmacology (<a href="#Section_12.3">12.3</a>)]</span>. Coadministration with
oral doses of a P-gp and CYP3A4 inhibitor, ketoconazole, increased
exposure to nintedanib by 60%. Concomitant use of P-gp and CYP3A4
inhibitors (e.g., erythromycin) with OFEV may increase exposure to
nintedanib <span class="Italics">[see Clinical Pharmacology (<a href="#Section_12.3">12.3</a>)]</span>. In such cases, patients
should be monitored closely for tolerability of OFEV. Management of
adverse reactions may require interruption, dose reduction, or discontinuation
of therapy with OFEV<span class="Italics"> [see Dosage and Administration (<a href="#Section_2.3">2.3</a>)]</span>.</p>
<p><a name="p87079281397666168"></a>Coadministration with oral doses of a P-gp
and CYP3A4 inducer, rifampicin, decreased exposure to nintedanib by
50%. Concomitant use of P-gp and CYP3A4 inducers (e.g., carbamazepine,
phenytoin, and St. John’s wort) with OFEV should be avoided as these
drugs may decrease exposure to nintedanib <span class="Italics">[see Clinical Pharmacology
(<a href="#Section_12.3">12.3</a>)].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_7.2"></a><a name="section-7.2"></a><p></p>
<h2>7.2  Anticoagulants</h2>
<p class="First"><a name="p164023281413559323"></a>Nintedanib is a VEGFR inhibitor, and may
increase the risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. Monitor patients on full anticoagulation
therapy closely for <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> and adjust anticoagulation treatment
as necessary <span class="Italics">[see Warnings and Precautions (<a href="#Section_5.5">5.5</a>)].</span></p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="Section_8"></a><a name="section-8"></a><p></p>
<h1>8  USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="Section_8.1"></a><a name="section-8.1"></a><p></p>
<h2>8.1  Pregnancy</h2>
<p class="First"><a name="P15"></a><span class="Italics">Pregnancy Category D. [See <span class="Italics">Warnings and Precautions</span> (<a href="#Section_5.3">5.3</a>)]</span></p>
<p><a name="p7944281397666407"></a>OFEV can cause fetal harm when administered
to a pregnant woman. If OFEV is used during pregnancy, or if the patient
becomes pregnant while taking OFEV, the patient should be apprised
of the potential hazard to a fetus. Women of childbearing potential
should be advised to avoid becoming pregnant while receiving treatment
with OFEV.</p>
<p><a name="p46323281413559438"></a>In animal
reproduction toxicity studies, nintedanib caused embryofetal <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span>
and teratogenic effects in rats and rabbits at less than and approximately
5 times the maximum recommended human dose (MRHD) in adults (on a
plasma AUC basis at maternal oral doses of 2.5 and 15 mg/kg/day in
rats and rabbits, respectively). Malformations included abnormalities
in the vasculature, urogenital, and skeletal systems. Vasculature
anomalies included missing or additional major blood vessels. Skeletal
anomalies included abnormalities in the thoracic, lumbar, and caudal
vertebrae (e.g., hemivertebra, missing, or asymmetrically ossified),
ribs (bifid or fused), and sternebrae (fused, split, or unilaterally
ossified). In some fetuses, organs in the urogenital system were missing.
In rabbits, a significant change in sex ratio was observed in fetuses
(female:male ratio of approximately 71%:29%) at approximately 15 times
the MRHD in adults (on an AUC basis at a maternal oral dose of 60
mg/kg/day). Nintedanib decreased post-natal viability of rat pups
during the first 4 post-natal days when dams were exposed to less
than the MRHD (on an AUC basis at a maternal oral dose of 10 mg/kg/day).</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="Section_8.3"></a><a name="section-8.2"></a><p></p>
<h2>8.3  Nursing Mothers</h2>
<p class="First"><a name="P17"></a>Nintedanib and/or its metabolites are excreted into the milk
of lactating rats. Milk and plasma of lactating rats have similar
concentrations of nintedanib and its metabolites. Excretion of nintedanib
and/or its metabolites into human milk is probable. There are no human
studies that have investigated the effects of OFEV on breast-fed infants.
Because of the potential for serious adverse reactions in nursing
infants from OFEV, a decision should be made whether to discontinue
nursing or to discontinue the drug, taking into account the importance
of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="Section_8.4"></a><a name="section-8.3"></a><p></p>
<h2>8.4  Pediatric Use</h2>
<p class="First"><a name="P18"></a>Safety and effectiveness in pediatric patients have not been
established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="Section_8.5"></a><a name="section-8.4"></a><p></p>
<h2>8.5  Geriatric Use</h2>
<p class="First"><a name="P19"></a>Of the total number of subjects in phase 2 and 3 clinical
studies of OFEV, 60.8% were 65 and over, while 16.3% were 75 and over.
In phase 3 studies, no overall differences in effectiveness were observed
between subjects who were 65 and over and younger subjects; no overall
differences in safety were observed between subjects who were 65 and
over or 75 and over and younger subjects, but greater sensitivity
of some older individuals cannot be ruled out.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_8.6"></a><a name="section-8.5"></a><p></p>
<h2>8.6  <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First"><a name="p873811281397666896"></a>Nintedanib is predominantly eliminated via
biliary/fecal excretion (&gt;90%)<span class="Italics"> [see Clinical Pharmacology
(<a href="#Section_12.3">12.3</a>)]</span>. No dedicated pharmacokinetic
(PK) study was performed in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. Monitor
for adverse reactions and consider dose modification or discontinuation
of OFEV as needed for patients with mild <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child
Pugh A). The safety and efficacy of nintedanib has not been investigated
in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> classified as Child Pugh B or
C. Therefore, treatment of patients with moderate (Child Pugh B) and
severe (Child Pugh C) <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> with OFEV is not recommended <span class="Italics">[see Warnings and Precautions (<a href="#Section_5.1">5.1</a>)].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_8.7"></a><a name="section-8.6"></a><p></p>
<h2>8.7  <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First"><a name="p87406281397666899"></a>Based on a single-dose study, less than 1%
of the total dose of nintedanib is excreted via the kidney <span class="Italics">[see Clinical Pharmacology (<a href="#Section_12.3">12.3</a>)]</span>. Adjustment of the starting dose in patients with mild
to moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> is not required. The safety, efficacy,
and pharmacokinetics of nintedanib have not been studied in patients
with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (&lt;30 mL/min CrCl) and end-stage renal
disease.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_8.8"></a><a name="section-8.7"></a><p></p>
<h2>8.8  Smokers</h2>
<p class="First"><a name="p1692611281413560103"></a>Smoking was associated with decreased exposure to OFEV <span class="Italics">[see
Clinical Pharmacology (<a href="#Section_12.3">12.3</a>)],</span> which may alter the efficacy profile of OFEV. Encourage patients
to stop smoking prior to treatment with OFEV and to avoid smoking
when using OFEV.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="Section_10"></a><a name="section-9"></a><p></p>
<h1>10  OVERDOSAGE</h1>
<p class="First"><a name="P24"></a>In the trials, one patient was inadvertently exposed to a dose of
600 mg daily for a total of 21 days. A non-serious adverse event (<span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">nasopharyngitis</span>)
occurred and resolved during the period of incorrect dosing, with
no onset of other reported events. <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">Overdose</span> was also reported in two
patients in oncology studies who were exposed to a maximum of 600
mg twice daily for up to 8 days. Adverse events reported were consistent
with the existing safety profile of OFEV. Both patients recovered.
In case of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, interrupt treatment and initiate general supportive
measures as appropriate.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="Section_11"></a><a name="section-10"></a><p></p>
<h1>11  DESCRIPTION</h1>
<p class="First"><a name="p38614281413560149"></a>OFEV capsules contain nintedanib,
a kinase inhibitor <span class="Italics">[see Mechanism of Action (12.1)].</span> Nintedanib is presented as the ethanesulfonate salt (esylate), with
the chemical name 1<span class="Italics">H</span>-Indole-6-carboxylic acid, 2,3-dihydro-3-[[[4-[methyl[(4-methyl-1-piperazinyl)acetyl]amino]phenyl]amino]phenylmethylene]-2-oxo-,methyl
ester, (3<span class="Italics">Z</span>)-, ethanesulfonate (1:1).</p>
<p><a name="P25"></a>Its structural formula is:<br><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=da1c9f37-779e-4682-816f-93d0faa4cfc9&amp;name=tradename-structure.jpg"></p>
<p><a name="p38524281413560165"></a>Nintedanib esylate
is a bright yellow powder with an empirical formula of C<span class="Sub">31</span>H<span class="Sub">33</span>N<span class="Sub">5</span>O<span class="Sub">4</span>·C<span class="Sub">2</span>H<span class="Sub">6</span>O<span class="Sub">3</span>S and a molecular weight of 649.76 g/mol.</p>
<p><a name="p361415281397667238"></a>OFEV capsules for oral administration
are available in 2 dose strengths containing 100 mg or 150 mg of nintedanib
(equivalent to 120.40 mg or 180.60 mg nintedanib ethanesulfonate,
respectively). The inactive ingredients of OFEV are the following:
Fill Material: triglycerides, hard fat, lecithin. Capsule Shell: gelatin,
glycerol, titanium dioxide, red ferric oxide, yellow ferric oxide,
black ink.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="Section_12"></a><a name="section-11"></a><p></p>
<h1>12  CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="Section_12.1"></a><a name="section-11.1"></a><p></p>
<h2>12.1  Mechanism of Action</h2>
<p class="First"><a name="P27"></a>Nintedanib is a small molecule that inhibits multiple receptor
tyrosine kinases (RTKs) and non-receptor tyrosine kinases (nRTKs).
Nintedanib inhibits the following RTKs: platelet-derived growth factor
receptor (PDGFR) α and β, fibroblast growth factor receptor (FGFR)
1-3, vascular endothelial growth factor receptor (VEGFR) 1-3, and
Fms-like tyrosine kinase-3 (FLT3). Among them, FGFR, PDGFR, and VEGFR
have been implicated in IPF pathogenesis. Nintedanib binds competitively
to the adenosine triphosphate (ATP) binding pocket of these receptors
and blocks the intracellular signaling which is crucial for the proliferation,
migration, and transformation of fibroblasts representing essential
mechanisms of the IPF pathology. In addition, nintedanib inhibits
the following nRTKs: Lck, Lyn and Src kinases. The contribution of
FLT3 and nRTK inhibition to IPF efficacy is unknown.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="Section_12.2"></a><a name="section-11.2"></a><p></p>
<h2>12.2  Pharmacodynamics</h2>
<p class="First"><a name="p2050224"></a><span class="Underline">Cardiac Electrophysiology</span><br>In a
study in renal cell cancer patients, QT/QTc measurements were recorded
and showed that a single oral dose of 200 mg nintedanib as well as
multiple oral doses of 200 mg nintedanib administered twice daily
for 15 days did not prolong the QTcF interval.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="Section_12.3"></a><a name="section-11.3"></a><p></p>
<h2>12.3  Pharmacokinetics</h2>
<p class="First"><a name="P28"></a>The PK properties of nintedanib were similar in healthy volunteers,
patients with IPF, and cancer patients. The PK of nintedanib is linear.
Dose proportionality was shown by an increase of nintedanib exposure
with increasing doses (dose range 50 to 450 mg once daily and 150
to 300 mg twice daily). Accumulation upon multiple administrations
in patients with IPF was 1.76-fold for AUC. Steady-state plasma concentrations
were achieved within one week of dosing. Nintedanib trough concentrations
remained stable for more than one year. The inter-individual variability
in the PK of nintedanib was moderate to high (coefficient of variation
of standard PK parameters in the range of 30% to 70%), intra-individual
variability low to moderate (coefficients of variation below 40%).</p>
<p><a name="p33413281397667457"></a><span class="Underline">Absorption</span><br>Nintedanib reached maximum plasma concentrations approximately
2 to 4 hours after oral administration as a soft gelatin capsule under
fed conditions. The absolute bioavailability of a 100 mg dose was
4.7% (90% CI: 3.62 to 6.08) in healthy volunteers. Absorption and
bioavailability are decreased by transporter effects and substantial
first-pass metabolism.</p>
<p><a name="p871912281397667527"></a>After food intake, nintedanib exposure increased by approximately
20% compared to administration under fasted conditions (90% CI: 95.3%
to 152.5%) and absorption was delayed (median t<span class="Sub">max</span> fasted: 2.00 hours; fed: 3.98 hours), irrespective of the food type.</p>
<p><a name="p87271281397667545"></a><span class="Underline">Distribution</span><br>Nintedanib follows bi-phasic disposition kinetics. After
intravenous infusion, a high volume of distribution which was larger
than total body volume (V<span class="Sub">ss</span>: 1050 L) was observed.</p>
<p><a name="p874110281397667572"></a>The <span class="Italics">in vitro</span> protein binding of nintedanib in human plasma was high, with a bound
fraction of 97.8%. Serum albumin is considered to be the major binding
protein. Nintedanib is preferentially distributed in plasma with a
blood to plasma ratio of 0.87.</p>
<p><a name="p89745281397667680"></a><span class="Underline">Elimination</span><br>The effective half-life of nintedanib in patients with IPF was 9.5
hours (gCV 31.9%). Total plasma clearance after intravenous infusion
was high (CL: 1390 mL/min; gCV 28.8%). Urinary excretion of unchanged
drug within 48 hours was about 0.05% of the dose after oral and about
1.4% of the dose after intravenous administration; the renal clearance
was 20 mL/min.</p>
<p><a name="p89795281397667607"></a><span class="Italics">Metabolism</span><br>The prevalent metabolic reaction for
nintedanib is hydrolytic cleavage by esterases resulting in the free
acid moiety BIBF 1202. BIBF 1202 is subsequently glucuronidated by
UGT enzymes, namely UGT 1A1, UGT 1A7, UGT 1A8, and UGT 1A10 to BIBF
1202 glucuronide. Only a minor extent of the biotransformation of
nintedanib consisted of CYP pathways, with CYP 3A4 being the predominant
enzyme involved. The major CYP-dependent metabolite could not be detected
in plasma in the human absorption, distribution, metabolism, and elimination
study. <span class="Italics">In vitro</span>, CYP-dependent metabolism accounted
for about 5% compared to about 25% ester cleavage.</p>
<p><a name="p56623281413560388"></a><span class="Italics">Excretion</span><br>The
major route of elimination of drug-related radioactivity after oral
administration of [<span class="Sup">14</span>C] nintedanib was
via fecal/biliary excretion (93.4% of dose), and the majority of OFEV
was excreted as BIBF 1202. The contribution of renal excretion to
the total clearance was low (0.65% of dose). The overall recovery
was considered complete (above 90%) within 4 days after dosing.</p>
<p><a name="p90004281397667811"></a><span class="Underline">Specific Populations</span><br><span class="Italics">Age, Body Weight, and Sex</span><br>Based on population PK analysis, age and body weight were correlated
with nintedanib exposure. However, their effects on exposure are not
sufficient to warrant a dose adjustment. There was no influence of
sex on the exposure of nintedanib.</p>
<p><a name="p92204281397667951"></a><span class="Italics"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span><br>Based on a population PK analysis of data from 933 patients with
IPF, exposure to nintedanib was not influenced by mild (CrCl: 60 to
90 mL/min; n=399) or moderate (CrCl: 30 to 60 mL/min; n=116) renal
impairment. Data in severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (CrCl below 30 mL/min)
was limited.</p>
<p><a name="p90074281397667841"></a><span class="Italics"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></span><br>No dedicated PK study was
conducted in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. As nintedanib is eliminated
primarily by biliary/fecal excretion (&gt;90%), <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> is
likely to increase plasma nintedanib concentrations. Clinical studies
excluded patients with AST or ALT greater than 1.5 times ULN. Patients
with total bilirubin greater than 1.5 times ULN were also excluded.
Therefore, monitor for adverse reactions and consider dose modification
or discontinuation of OFEV as needed for patients with mild hepatic
impairment.</p>
<p><a name="p92274281397668007"></a><span class="Italics">Smokers</span><br>In the population PK analysis, the exposure
of nintedanib was 21% lower in current smokers compared to ex- and
never-smokers. The effect is not sufficient to warrant a dose adjustment.</p>
<p><a name="p92344281397668048"></a><span class="Underline">Drug Interaction Studies</span><br><span class="Italics">Potential for Nintedanib to Affect Other Drugs</span><br>Effect of nintedanib coadministration on pirfenidone
AUC and C<span class="Sub">max</span> was evaluated in a multiple-dose
study. Nintedanib did not have an effect on the exposure of pirfenidone.</p>
<p><a name="p92534281397668104"></a>In<span class="Italics"> in vitro</span> studies,
nintedanib was shown not to be an inhibitor of OATP-1B1, OATP-1B3,
OATP-2B1, OCT-2, or MRP-2. <span class="Italics">In vitro </span>studies also
showed that nintedanib has weak inhibitory potential on OCT-1, BCRP,
and P-gp; these findings are considered to be of low clinical relevance.
Nintedanib and its metabolites, BIBF 1202 and BIBF 1202 glucuronide,
did not inhibit or induce CYP enzymes <span class="Italics">in vitro</span>.</p>
<p><a name="p92543281397668138"></a><span class="Italics">Potential for Other Drugs
to Affect Nintedanib</span><br>Nintedanib is a substrate
of P-gp and, to a minor extent, CYP3A4. Coadministration with the
P-gp and CYP3A4 inhibitor, ketoconazole, increased exposure to nintedanib
1.61-fold based on AUC and 1.83-fold based on C<span class="Sub">max</span> in a dedicated drug-drug interaction study. In a drug-drug interaction
study with the P-gp and CYP3A4 inducer, rifampicin, exposure to nintedanib
decreased to 50.3% based on AUC and to 60.3% based on C<span class="Sub">max</span> upon coadministration with rifampicin compared to
administration of nintedanib alone.</p>
<p><a name="p212624281413560784"></a>Based on a multiple-dose study in Japanese
IPF patients, exposure to nintedanib decreased to 68.3% based on AUC
and to 59.2% based on C<span class="Sub">max</span> upon coadministration
with pirfenidone compared to administration of nintedanib alone.</p>
<p><a name="p212598281413560783"></a>Nintedanib displays a pH-dependent
solubility profile with increased solubility at acidic pH&lt;3. However,
in the clinical trials, coadministration with proton pump inhibitors
or histamine H2 antagonists did not influence the exposure (trough
concentrations) of nintedanib.</p>
<p><a name="p59065281413560781"></a>In <span class="Italics">in vitro</span> studies, nintedanib
was shown not to be a substrate of OATP-1B1, OATP-1B3, OATP-2B1, OCT-2,
MRP-2, or BCRP. <span class="Italics">In vitro</span> studies also showed that
nintedanib was a substrate of OCT-1; these findings are considered
to be of low clinical relevance.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="Section_13"></a><a name="section-12"></a><p></p>
<h1>13  NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="Section_13.1"></a><a name="section-12.1"></a><p></p>
<h2>13.1  Carcinogenesis, Mutagenesis, Impairment of
Fertility</h2>
<p class="First"><a name="P30"></a>Two-year oral carcinogenicity
studies of nintedanib in rats and mice have not revealed any evidence
of carcinogenic potential. Nintedanib was dosed up to 10 and 30 mg/kg/day
in rats and mice, respectively. These doses were less than and approximately
4 times the MRHD on a plasma drug AUC basis.</p>
<p><a name="p13298281397668231"></a>Nintedanib was negative for genotoxicity in
the <span class="Italics">in vitro</span> bacterial reverse mutation assay, the
mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> cell forward mutation assay, and the <span class="Italics">in vivo</span> rat micronucleus assay.</p>
<p><a name="p947710281397668241"></a>In rats, nintedanib reduced female fertility at exposure levels approximately
3 times the MRHD (on an AUC basis at an oral dose of 100 mg/kg/day).
Effects included increases in resorption and post-implantation loss,
and a decrease in gestation index. Changes in the number and size
of corpora lutea in the ovaries were observed in chronic toxicity
studies in rats and mice. An increase in the number of females with
resorptions only was observed at exposures approximately equal to
the MRHD (on an AUC basis at an oral dose of 20 mg/kg/day). Nintedanib
had no effects on male fertility in rats at exposure levels approximately
3 times the MRHD (on an AUC basis at an oral dose of 100 mg/kg/day).</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="Section_14"></a><a name="section-13"></a><p></p>
<h1>14  CLINICAL STUDIES</h1>
<p class="First"><a name="p171944281413560876"></a>The clinical efficacy of OFEV has been studied
in 1231 patients with IPF in one phase 2 (Study 1) and two phase 3
(Studies 2 and 3). These were randomized, double-blind, placebo-controlled
studies comparing treatment with OFEV 150 mg twice daily to placebo
for 52 weeks.</p>
<p><a name="p212813281413560883"></a>Studies
2 and 3 were identical in design. Study 1 was very similar in design.
Patients were randomized in a 3:2 ratio (1:1 for Study 1) to either
OFEV 150 mg or placebo twice daily for 52 weeks. Study 1 also included
other treatment arms (50 mg daily, 50 mg twice daily, and 100 mg twice
daily) that are not further discussed. The primary endpoint was the
annual rate of decline in Forced <span class="product-label-link" type="condition" conceptid="4147814" conceptname="Vital capacity">Vital Capacity</span> (FVC). Time to first
acute IPF exacerbation was a key secondary endpoint in Studies 2 and
3 and a secondary endpoint in Study 1. Change from baseline in FVC
percent predicted and survival were additional secondary endpoints
in all studies.</p>
<p><a name="p212845281413560882"></a>Patients
were required to have a diagnosis of IPF (ATS/ERS/JRS/ALAT criteria)
for &lt;5 years. Diagnoses were centrally adjudicated based on radiologic
and, if applicable, histopathologic confirmation. Patients were required
to be ≥40 years of age with an FVC ≥50% of predicted and a carbon
monoxide diffusing capacity (DLCO, corrected for hemoglobin) 30% to
79% of predicted. Patients with relevant airways obstruction (i.e.,
pre-bronchodilator FEV<span class="Sub">1</span>/FVC &lt;0.7) or, in
the opinion of the investigator, likely to receive a lung transplant
during the studies were excluded (being listed for lung transplant
was acceptable for inclusion). Patients with &gt;1.5 times ULN of ALT,
AST, or bilirubin, patients with a known risk or predisposition to
<span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, patients receiving a full dose of anticoagulation treatment,
and patients with a recent history of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> or <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>
were excluded from the studies. Patients were also excluded if they
received other investigational therapy, azathioprine, cyclophosphamide,
or cyclosporine A within 8 weeks of entry into this trial, or n-acetyl
cysteine and prednisone (&gt;15 mg/day or equivalent) within 2 weeks.
The majority of patients were Caucasian (60%) or Asian (30%) and male
(79%). Patients had a mean age of 67 years and a mean FVC percent
predicted of 80%.</p>
<p><a name="p212892281413560983"></a><span class="Underline">Annual Rate of Decline in FVC</span><br>A statistically
significant reduction in the annual rate of decline of FVC (in mL)
was demonstrated in patients receiving OFEV compared to patients receiving
placebo based on the random coefficient regression model, adjusted
for gender, height, and age. The treatment effect on FVC was consistent
in all 3 studies. See Table 2 for individual study results.</p>
<a name="t15501328"></a><table border="0" frame="void" rules="none" width="100%">
<caption><span>Table 2 Annual Rate of Decline in FVC (mL) in Studies 1,
2, and 3<span class="Sup">a</span></span></caption>
<colgroup>
<col width="5%">
<col width="20%">
<col align="center" width="15%">
<col align="center" width="10%">
<col align="center" width="15%">
<col align="center" width="10%">
<col align="center" width="15%">
<col align="center" width="10%">
</colgroup>
<tfoot><tr class="First Last"><td colspan="8">
<span class="Sup">a</span>Randomized set in Study
1; treated set in Studies 2 and 3<br><span class="Sup">b</span>Estimated based on a random coefficient regression model</td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" colspan="2"> </td>
<td class="Botrule Lrule Rrule Toprule" align="left" colspan="2"><span class="Bold">Study 1</span></td>
<td class="Botrule Lrule Rrule Toprule" align="left" colspan="2"><span class="Bold">Study 2</span></td>
<td class="Botrule Lrule Rrule Toprule" align="left" colspan="2"><span class="Bold">Study 3</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" colspan="2"> </td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">OFEV<br>150 mg<br>twice daily</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><span class="Bold">Placebo</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">OFEV<br>150 mg<br>twice daily</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><span class="Bold">Placebo</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">OFEV<br>150 mg<br>twice daily</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><span class="Bold">Placebo</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" colspan="2">Number of analyzed
patients</td>
<td class="Botrule Lrule Rrule Toprule" align="center">84</td>
<td class="Botrule Lrule Rrule Toprule" align="center">83</td>
<td class="Botrule Lrule Rrule Toprule" align="center">309</td>
<td class="Botrule Lrule Rrule Toprule" align="center">204</td>
<td class="Botrule Lrule Rrule Toprule" align="center">329</td>
<td class="Botrule Lrule Rrule Toprule" align="center">219</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" colspan="2" valign="top">Rate<span class="Sup">a</span> of decline over 52 weeks</td>
<td class="Botrule Lrule Rrule Toprule" align="center">-60</td>
<td class="Botrule Lrule Rrule Toprule" align="center">-191</td>
<td class="Botrule Lrule Rrule Toprule" align="center">-115</td>
<td class="Botrule Lrule Rrule Toprule" align="center">-240</td>
<td class="Botrule Lrule Rrule Toprule" align="center">-114</td>
<td class="Botrule Lrule Rrule Toprule" align="center">-207</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" colspan="2">Comparison vs placebo</td>
<td class="Lrule Rrule Toprule" align="center" colspan="2"> </td>
<td class="Lrule Rrule Toprule" align="center" colspan="2"> </td>
<td class="Lrule Rrule Toprule" align="center" colspan="2"> </td>
</tr>
<tr>
<td class="Botrule Lrule"> </td>
<td class="Botrule Rrule">Difference<span class="Sup">b</span>
</td>
<td class="Botrule Lrule Rrule" align="center" colspan="2">131</td>
<td class="Botrule Lrule Rrule" align="center" colspan="2">125</td>
<td class="Botrule Lrule Rrule" align="center" colspan="2">94</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Toprule"> </td>
<td class="Botrule Rrule Toprule">95% CI</td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2">(27, 235)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2">(78, 173)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2">(45, 143)</td>
</tr>
</tbody>
</table>
<p><a name="p1767315281413561773"></a>Figure 1 displays the
change from baseline over time in both treatment groups for Study
2. When the mean observed FVC change from baseline was plotted over
time, the curves diverged at all timepoints through Week 52. Similar
plots were seen for Studies 1 and 3.</p>
<p><a name="p1768315281413561780"></a><span class="Bold">Figure 1 Mean (SEM) Observed FVC Change
from Baseline (mL) Over Time in Study 2</span></p>
<div class="Figure"><img alt="Figure 1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=da1c9f37-779e-4682-816f-93d0faa4cfc9&amp;name=ofev_figure-1.jpg"></div>
<p><a name="p1767513281413561836"></a>bid = twice daily</p>
<p><a name="p64275281413561852"></a><span class="Underline">Change from Baseline in Percent
Predicted Forced <span class="product-label-link" type="condition" conceptid="4147814" conceptname="Vital capacity">Vital Capacity</span></span><br>Figure 2 presents
the cumulative distribution for all cut-offs for the change from baseline
in FVC percent predicted at Week 52 for Study 2. For all categorical
declines in lung function, the proportion of patients declining was
lower on OFEV than on placebo. Study 3 showed similar results.</p>
<p><a name="p64226281413561866"></a><span class="Bold">Figure 2 Cumulative Distribution
of Patients by Change in Percent Predicted FVC from Baseline to Week
52 (Study 2).* The vertical lines indicate ≥0% decline or ≥10% decline.</span></p>
<div class="Figure"><img alt="Figure 2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=da1c9f37-779e-4682-816f-93d0faa4cfc9&amp;name=ofev_figure-2.jpg"></div>
<p><a name="p64183281413561916"></a>*Missing data for change from baseline at
Week 52 in percent predicted FVC (due to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, lost to follow-up
or censoring before 52 weeks) was imputed using the worst decline
from baseline at Week 52 observed among all patients with available
data, regardless of treatment.<br>bid = twice daily</p>
<p><a name="p64135281413561943"></a><span class="Underline">Time to First Acute
IPF Exacerbation</span><br>Acute IPF exacerbation was
defined as unexplained worsening or development of <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span> within
30 days, new diffuse pulmonary infiltrates on chest x-ray, and/or
new high-resolution CT parenchymal abnormalities with no <span class="product-label-link" type="condition" conceptid="253796" conceptname="Pneumothorax">pneumothorax</span>
or <span class="product-label-link" type="condition" conceptid="254061" conceptname="Pleural effusion">pleural effusion</span>, and exclusion of alternative causes. Acute IPF
exacerbation was adjudicated in Studies 2 and 3. In Studies 1 (investigator-reported)
and 3 (adjudicated), the risk of first acute IPF exacerbation over
52 weeks was significantly reduced in patients receiving OFEV compared
to placebo (hazard ratio [HR]: 0.16, 95% CI: 0.04, 0.71) and (HR:0.20,
95% CI: 0.07, 0.56), respectively. In Study 2 (adjudicated), there
was no difference between the treatment groups (HR: 0.55, 95% CI:
0.20, 1.54).</p>
<p><a name="p174491281413561953"></a><span class="Underline">Survival</span><br>Survival was evaluated for OFEV compared
to placebo in Studies 2 and 3 as an exploratory analysis to support
the primary endpoint (FVC). All-cause mortality was assessed over
the study duration and available follow-up period, irrespective of
cause of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> and whether patients continued treatment. All-cause
mortality did not show a statistically significant difference (See
Figure 3).</p>
<p><a name="p174381281413561974"></a><span class="Bold">Figure
3 Kaplan-Meier Estimates of All-Cause Mortality at Vital Status –
End of Study: Studies 2 and 3</span></p>
<div class="Figure"><img alt="Figure 3" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=da1c9f37-779e-4682-816f-93d0faa4cfc9&amp;name=ofev_figure-3.jpg"></div>
<p><a name="p1741115281413562015"></a>bid = twice daily</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="Section_16"></a><a name="section-14"></a><p></p>
<h1>16  HOW
SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First"><a name="P34"></a>150 mg:  brown, opaque, oblong, soft capsules imprinted in black
with the Boehringer Ingelheim company symbol and "150". They are packaged
in HDPE bottles with a child-resistant closure, available as follows:<br>Bottles of 60           NDC:  0597-0145-60</p>
<p><a name="p38895281397671902"></a>100 mg:  peach, opaque, oblong, soft capsules
imprinted in black with the Boehringer Ingelheim company symbol and
"100". They are packaged in HDPE bottles with a child-resistant closure,
available as follows:<br>Bottles of 60           NDC:  0597-0143-60</p>
<p><a name="p1382615281397671955"></a><span class="Italics">Storage</span><br><span class="Bold">Store at 25°C (77°F); excursions permitted to 15° to 30°C
(59° to 86°F)</span> [see USP Controlled Room Temperature]. Protect
from exposure to high humidity and avoid excessive heat. If repackaged,
use USP tight container. Keep out of reach of children.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="Section_17"></a><a name="section-15"></a><p></p>
<h1>17  PATIENT COUNSELING INFORMATION</h1>
<p class="First"><a name="P35"></a><span class="Italics">Advise the patient to read the FDA-approved
patient labeling (Patient Information).</span></p>
<p><a name="p115235281413562179"></a><span class="Underline">Liver Enzyme and Bilirubin Elevations</span><br>Advise patients that they will need to undergo liver
function testing periodically. Advise patients to immediately report
any symptoms of a liver problem (e.g., skin or the whites of eyes
turn yellow, urine turns dark or brown (tea colored), <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> on the
right side of stomach, bleed or <span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">bruise</span> more easily than normal, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>) <span class="Italics">[see Warnings and Precautions (<a href="#Section_5.1">5.1</a>)].</span></p>
<p><a name="p110283281413562215"></a><span class="Underline"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span></span><br>Inform patients
that <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal disorders</span> such as <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>
were the most commonly reported gastrointestinal events occurring
in patients who received OFEV. Advise patients that their healthcare
provider may recommend hydration, antidiarrheal medications (e.g.,
loperamide), or anti-emetic medications to treat these side effects.
Temporary dosage reductions or discontinuations may be required. Instruct
patients to contact their healthcare provider at the first signs of
<span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> or for any severe or persistent <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> <span class="Italics">[see Warnings and Precautions (<a href="#Section_5.2">5.2</a>) and Adverse Reactions (<a href="#Section_6.1">6.1</a>)].</span></p>
<p><a name="p110303281413562214"></a><span class="Underline">Pregnancy</span><br>Counsel patients on pregnancy planning and prevention.
Advise females of childbearing potential of the potential hazard to
a fetus and to avoid becoming pregnant while receiving treatment with
OFEV. Advise females of childbearing potential to use adequate contraception
during treatment, and for at least 3 months after taking the last
dose of OFEV. Advise female patients to notify their doctor if they
become pregnant during therapy with OFEV <span class="Italics">[see Warnings and
Precautions (<a href="#Section_5.3">5.3</a>) and Use in Specific
Populations (<a href="#Section_8.1">8.1</a>)].</span></p>
<p><a name="p110323281413562213"></a><span class="Underline">Arterial Thromboembolic
Events</span><br>Advise patients about the signs and
symptoms of <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">acute myocardial ischemia</span> and other arterial thromboembolic
events and the urgency to seek immediate medical care for these conditions <span class="Italics">[see Warnings and Precautions (<a href="#Section_5.4">5.4</a>)].</span></p>
<p><a name="p110343281413562212"></a><span class="Underline">Risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span></span><br><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> events have been
reported. Advise patients to report unusual <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> <span class="Italics">[see
Warnings and Precautions (<a href="#Section_5.5">5.5</a>)].</span></p>
<p><a name="p110363281413562211"></a><span class="Underline">Gastrointestinal
Perforation</span><br>Serious <span class="product-label-link" type="condition" conceptid="4202064" conceptname="Gastrointestinal perforation">gastrointestinal perforation</span>
events have been reported. Advise patients to report signs and symptoms
of <span class="product-label-link" type="condition" conceptid="4202064" conceptname="Gastrointestinal perforation">gastrointestinal perforation</span> <span class="Italics">[see Warnings and Precautions
(<a href="#Section_5.6">5.6</a>)]</span>.</p>
<p><a name="p110383281413562210"></a><span class="Underline">Nursing Mothers</span><br>Advise patients to discontinue nursing while taking OFEV or discontinue
OFEV while nursing <span class="Italics">[see Use in Specific Populations (<a href="#Section_8.3">8.3</a>)].</span></p>
<p><a name="p110403281413562209"></a><span class="Underline">Smokers</span><br>Encourage patients to stop smoking prior to treatment with OFEV
and to avoid smoking when using with OFEV <span class="Italics">[see Clinical Pharmacology
(<a href="#Section_12.3">12.3</a>)]</span>.</p>
<p><a name="p110423281413562207"></a><span class="Underline">Administration</span><br>Instruct patients to swallow OFEV capsules whole with liquid and
not to chew or crush the capsules due to the bitter taste<span class="Italics">.</span> Advise patients to not make up for a missed dose <span class="Italics">[see Dosage
and Administration (<a href="#Section_2">2</a>)]</span>.</p>
<br><p><a name="p143450281397672370"></a>Distributed by:<br>Boehringer Ingelheim Pharmaceuticals, Inc.<br>Ridgefield,
CT 06877 USA</p>
<p><a name="p141180281397672397"></a>Licensed
from:<br>Boehringer Ingelheim International GmbH</p>
<p><a name="p140943281397672412"></a>OFEV is a registered trademark
of and used under license from Boehringer Ingelheim International
GmbH.</p>
<p><a name="p148726281397672420"></a>Copyright © 2014 Boehringer Ingelheim International GmbH<br>ALL RIGHTS RESERVED</p>
<p><a name="p151043281397672442"></a>IT5950BJ142014<br>10009642/02</p>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="Section_19"></a><a name="section-16"></a><p></p>
<a name="t11564428"></a><table border="0" frame="void" rules="none" width="100%">
<colgroup><col></colgroup>
<tfoot><tr class="First Last"><td>This Patient Information has been approved by the U.S. Food and
Drug Administration.</td></tr></tfoot>
<tbody class="Headless">
<tr class="First"><td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">Patient
Information<br>OFEV<span class="Sup">®</span> (OH-fev)<br>(nintedanib)<br>capsules</span></td></tr>
<tr><td class="Botrule Lrule Rrule Toprule">Read this Patient Information
before you start taking OFEV and each time you get a refill. There
may be new information. This information does not take the place of
talking to your doctor about your medical condition or your treatment.</td></tr>
<tr><td class="Lrule Rrule Toprule"><span class="Bold">What is the most important information
I should know about OFEV?</span></td></tr>
<tr><td class="Botrule Lrule Rrule">OFEV can cause <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span> or
<span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> to an unborn baby. Women should not become pregnant while taking
OFEV. Women who are able to become pregnant should use birth control
during treatment and for at least 3 months after treatment. If you
become pregnant while taking OFEV, tell your doctor right away.</td></tr>
<tr><td class="Lrule Rrule Toprule"><span class="Bold">What is OFEV?</span></td></tr>
<tr><td class="Botrule Lrule Rrule"><ul class="Disc">
<li>OFEV is a prescription medicine used to treat people with
a <span class="product-label-link" type="condition" conceptid="257907" conceptname="Disorder of lung">lung disease</span> called <span class="product-label-link" type="condition" conceptid="45763750" conceptname="Idiopathic pulmonary fibrosis">idiopathic pulmonary fibrosis</span> (IPF).</li>
<li>It is not known if OFEV is safe and effective in children.</li>
</ul></td></tr>
<tr><td class="Lrule Rrule Toprule"><span class="Bold">What should I tell my doctor
before taking OFEV?</span></td></tr>
<tr><td class="Lrule Rrule"><span class="Bold">Before you take OFEV, tell your doctor
if you:</span></td></tr>
<tr><td class="Lrule Rrule"><ul class="Disc">
<li>have liver problems</li>
<li>have heart problems</li>
<li>have a history of blood clots</li>
<li>have a <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> problem or a family history of a <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>
problem</li>
<li>have had recent surgery in your stomach (abdominal) area</li>
<li>are a smoker</li>
<li>have any other medical conditions</li>
<li>are pregnant or plan to become pregnant. OFEV can harm your
unborn baby. OFEV can cause <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span> or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> to an unborn baby.
See <span class="Bold">“What is the most important information I should know about
OFEV??</span>
</li>
<li>are breastfeeding or plan to breastfeed. It is not known
if OFEV passes into your breast milk. You and your doctor should decide
if you will take OFEV or breastfeed. You should not do both.</li>
</ul></td></tr>
<tr><td class="Botrule Lrule Rrule">
<span class="Bold">Tell your doctor about all
the medicines you take,</span> including prescription and over-the-counter
medicines, vitamins, and herbal supplements such as St. John’s wort.
Keep a list of the medicines you take and show it to your doctor and
pharmacist when you get a new medicine.</td></tr>
<tr><td class="Lrule Rrule Toprule"><span class="Bold">How should I take OFEV?</span></td></tr>
<tr><td class="Lrule Rrule"><ul class="Disc">
<li>Take OFEV exactly as your doctor tells you to take it.</li>
<li>Your doctor will tell you how much OFEV to take and when
to take it.</li>
<li>Take OFEV with food. Swallow the OFEV capsules whole with
a liquid.</li>
<li>
<span class="Bold">Do not</span> chew or crush OFEV capsules.</li>
<li>If you miss a dose of OFEV, take your next dose at your
regular time. <span class="Bold">Do not</span> take the missed dose.</li>
<li>
<span class="Bold">Do not</span> take more than 300 mg of OFEV in 1 day.</li>
<li>If you take too much OFEV, call your doctor or go to the
nearest hospital emergency room right away.</li>
<li>Your doctor should do certain blood tests before you start
taking OFEV.</li>
</ul></td></tr>
<tr><td class="Lrule Rrule Toprule"><span class="Bold">What are the possible side effects
of OFEV?</span></td></tr>
<tr><td class="Lrule Rrule"><span class="Bold">OFEV may cause serious side effects,
including:</span></td></tr>
<tr><td class="Lrule Rrule"><ul class="Disc">
<li><span class="Bold">See “What is the most important information I should
know about OFEV??</span></li>
<li>
<span class="Bold">liver problems.</span> Call your doctor right away
if you have unexplained symptoms such as yellowing of your skin or
the white part of your eyes (<span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>), dark or brown (tea colored)
urine, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> on the upper right side of your stomach area (abdomen),
<span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> or <span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">bruising</span> more easily than normal, or feeling tired.<br>Your doctor will do blood tests regularly to check how well your
liver function is working during your treatment with OFEV.</li>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>.</span> While you are
taking OFEV, your doctor may recommend that you drink fluids or take
medicine to treat these side effects. Tell your doctor if you have
<span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> or if these symptoms do not go away
or become worse. Tell your doctor if you are taking over-the-counter
laxatives, stool softeners, and other medicines or dietary supplements
that can cause <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>.</li>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span>.</span> Tell your doctor right away if
you have symptoms of a heart problem. These symptoms may include chest
<span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> or pressure, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in your arms, back, neck or jaw, or shortness
of breath.</li>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>.</span> Tell your doctor right away if you
have symptoms of a <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>. These symptoms may include <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span> or
<span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> on 1 side of your body, trouble talking, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, or <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>.</li>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> problems.</span> OFEV may increase your chances
of having <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> problems. Tell your doctor if you have unusual
<span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, <span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">bruising</span>, or <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wounds</span> that do not heal. Tell your doctor if
you are taking a blood thinner, including prescription blood thinners
and over-the-counter aspirin.</li>
<li>
<span class="Bold">tear in your stomach or intestinal wall (perforation).</span> OFEV may increase your chances of having a tear in your stomach
or intestinal wall. Tell your doctor if you have <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> or <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>
in your stomach area.</li>
</ul></td></tr>
<tr><td class="Botrule Lrule Rrule">The most common side effects of
OFEV are <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach pain</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, liver problems,
<span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">decreased appetite</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, and <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span>.<br>These are
not all the possible side effects of OFEV. For more information, ask
your doctor or pharmacist.<br>Call your doctor for medical
advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</td></tr>
<tr><td class="Lrule Rrule Toprule"><span class="Bold">How should I store OFEV?</span></td></tr>
<tr><td class="Lrule Rrule"><ul class="Disc">
<li>Store OFEV at room temperature between 68°F to 77°F (20°C
to 25°C).</li>
<li>Keep OFEV dry and protect from high heat.</li>
<li>Safely throw away any OFEV that is out of date or no longer
needed.</li>
</ul></td></tr>
<tr><td class="Botrule Lrule Rrule"><span class="Bold">Keep OFEV and all medicines
out of reach of children.</span></td></tr>
<tr><td class="Lrule Rrule Toprule"><span class="Bold">General information about the
safe and effective use of OFEV.</span></td></tr>
<tr><td class="Botrule Lrule Rrule">
<ul class="Disc">
<li>Medicines are sometimes prescribed for purposes other than
those listed in a Patient Information leaflet. Do not use OFEV for
any condition for which it was not prescribed. Do not give OFEV to
other people, even if they have the same symptoms you have. It may
harm them. This Patient Information leaflet summarizes the most important
information about OFEV. If you would like more information, talk to
your doctor. You can ask your pharmacist or doctor for information
about OFEV that is written for health professionals.</li>
<li>For more information, go to <a href="#http://www.ofev.com/">www.ofev.com</a> or call Boehringer Ingelheim Pharmaceuticals,
Inc. at 1-800-542-6257, or (TTY) 1-800-459-9906, or scan the code
below to go to <a href="#http://www.ofev.com">www.ofev.com</a>.</li>
</ul>
<img alt="SCAN HERE" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=da1c9f37-779e-4682-816f-93d0faa4cfc9&amp;name=ofev_qr-code.jpg">
</td></tr>
<tr><td class="Lrule Rrule Toprule">
<span class="Bold">What are the ingredients in OFEV?</span><br><span class="Bold">Active ingredient:</span> nintedanib.<br><span class="Bold">Inactive ingredients:</span> Fill Material: triglycerides,
hard fat, lecithin. Capsule Shell: gelatin, glycerol, titanium dioxide,
red ferric oxide, yellow ferric oxide, black ink.</td></tr>
<tr class="Last"><td class="Botrule Lrule Rrule">Distributed by: Boehringer Ingelheim
Pharmaceuticals, Inc. Ridgefield, CT 06877 USA<br>OFEV is
a registered trademark of and used under license from Boehringer Ingelheim
International GmbH.<br>Copyright © 2014 Boehringer Ingelheim
International GmbH, ALL RIGHTS RESERVED<br>Issued: October
2014<br>IT5950BJ142014, 10009642/02</td></tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="gc391ea49-cfce-7a0b-f413-9feba5072fb4"></a><a name="section-17"></a><p></p>
<p class="First"><a name="p214281397674143"></a>OFEV 150
mg Label</p>
<p><a name="p143281397674157"></a>NDC 0597-0145-60</p>
<div class="Figure"><img alt="150 mg Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=da1c9f37-779e-4682-816f-93d0faa4cfc9&amp;name=ofev-150mg-label.jpg"></div>
<p><a name="p253281413569152"></a>OFEV 150 mg Carton</p>
<p><a name="p291281413569167"></a>NDC 0597-0145-60</p>
<div class="Figure"><img alt="150 mg Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=da1c9f37-779e-4682-816f-93d0faa4cfc9&amp;name=ofev-150mg-carton.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ge4fcc4bc-5636-43d6-029e-69db34f09e91"></a><a name="section-18"></a><p></p>
<p class="First"><a name="p214281397674291"></a>OFEV 100
mg Label</p>
<p><a name="p203281397674293"></a>NDC 0597-0143-60</p>
<div class="Figure"><img alt="100 mg Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=da1c9f37-779e-4682-816f-93d0faa4cfc9&amp;name=ofev-100mg-label.jpg"></div>
<p><a name="p264281413569357"></a>OFEV 100 mg Carton</p>
<div class="Figure"><img alt="100 mg Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=da1c9f37-779e-4682-816f-93d0faa4cfc9&amp;name=ofev-100mg-carton.jpg"></div>
<p><a name="p253281413569359"></a>NDC 0597-0143-60</p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>OFEV 		
					</strong><br><span class="contentTableReg">nintedanib capsule</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0597-0143</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>NINTEDANIB</strong> (NINTEDANIB) </td>
<td class="formItem">NINTEDANIB</td>
<td class="formItem">100 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">PINK (peach) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL</td>
<td class="formLabel">Size</td>
<td class="formItem">16mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">100</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0597-0143-60</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">60  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA205832</td>
<td class="formItem">10/28/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>OFEV 		
					</strong><br><span class="contentTableReg">nintedanib capsule</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0597-0145</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>NINTEDANIB</strong> (NINTEDANIB) </td>
<td class="formItem">NINTEDANIB</td>
<td class="formItem">150 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">BROWN</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL</td>
<td class="formLabel">Size</td>
<td class="formItem">18mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">150</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0597-0145-60</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">60  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA205832</td>
<td class="formItem">10/28/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Boehringer Ingelheim Pharmaceuticals, Inc.
							(603175944)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant - </span>Boehringer Ingelheim Pharmaceuticals, Inc. (603175944)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Boehringer Ingelheim Pharma GmbH &amp; Co. KG</td>
<td class="formItem"></td>
<td class="formItem">551147440</td>
<td class="formItem">ANALYSIS(0597-0143, 0597-0145), API MANUFACTURE(0597-0143, 0597-0145), LABEL(0597-0145, 0597-0143), PACK(0597-0143, 0597-0145)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Boehringer Ingelheim Roxane, Inc.</td>
<td class="formItem"></td>
<td class="formItem">058839929</td>
<td class="formItem">ANALYSIS(0597-0143, 0597-0145), LABEL(0597-0145, 0597-0143), PACK(0597-0143, 0597-0145)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Catalent Germany Eberbach GmbH</td>
<td class="formItem"></td>
<td class="formItem">318612223</td>
<td class="formItem">ANALYSIS(0597-0143, 0597-0145), MANUFACTURE(0597-0143, 0597-0145)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 10/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>fb8b3d0f-2437-49ae-948e-9245cc97cf8b</div>
<div>Set id: da1c9f37-779e-4682-816f-93d0faa4cfc9</div>
<div>Version: 2</div>
<div>Effective Time: 20141023</div>
</div>
</div> <div class="DistributorName">Boehringer Ingelheim Pharmaceuticals, Inc.</div></p>
</body></html>
